On Thursday, Arch Coal Inc (NYSE:ACI)’s shares declined -7.20% to $0.470.
Arch Coal Inc (ACI) declared that it received notice on May 21, 2015 from the New York Stock Exchange that it does not presently satisfy the NYSE’s continued listing standard requiring the average closing price of a listed company’s common stock to be at least $1.00 per share for any period of 30 successive trading days. As of May 15, 2015, the average closing price per share of the Company’s common stock over the preceding 30 trading-day period was $0.99.
In accordance with NYSE rules, the Company will respond to the NYSE within 10 business days of receipt of the notification with its intent to resolve the deficiency. The Company has six months to regain compliance with the NYSE continued listing requirements and will actively monitor its stock price and evaluate all accessible options in order to regain compliance within the prescribed timeframe.
During the six-month period the Company’s common stock will continue to be listed and traded on the NYSE, subject to compliance with other continued listing standards. The deficiency does not affect the Company’s ongoing business operations or its SEC reporting requirements.
Arch Coal, Inc. produces and sells thermal and metallurgical coal from surface and underground mines located in the United States. As of December 31, 2014, it operated or contracted out the operation of 16 mines; and owned or controlled about 5.1 billion tons of proven and probable recoverable reserves.
Actinium Pharmaceuticals Inc (NYSEMKT:ATNM)’s shares dropped -6.61% to $3.53.
Actinium Pharmaceuticals Inc (ATNM) sponsored the 9th Symposium on Targeted Alpha Therapy, held in Warsaw, Poland on May 19-21. Symposium organizers comprised of the Institute for Transuranium Elements of the European Commission and other sponsors comprise the U.S. Department of Energy. The latest developments in alpha emitter therapy were talk about, such as clinical experiences with alpha emitters counting actinium.
Dr. Joseph G. Jurcic, Professor of Medicine at Columbia University Medical Center and Chairman of Actinium’s Clinical Advisory Board, presented “Targeted Alpha-Particle Therapy with Actinium-225 (225Ac)-Lintuzumab for Acute Myeloid Leukemia (AML) Alone and in Combination with Low-Dose Cytarabine (LDAC)”. A review of the target (CD33), the antibody (Lintuzumab, also called HuM195) and the payload (actinium-225, a potent alpha-emitter) was given. He also offered a clinical update on the ongoing Phase I/II study of Actimab-A, the Company’s alpha-emitting radiolabeled antibody, being developed for older patients with newly diagnosed acute myeloid leukemia (AML).
Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs for the treatment of cancer. The company develops therapies for life threatening diseases using its alpha particle immunotherapy platform and other related and similar technologies.
At the end of Thursday’s trade, Thompson Creek Metals Company Inc (USA) (NYSE:TC)‘s shares dipped -6.34% to $0.890.
Thompson Creek Metals Company Inc (USA) (TC) declared that it has satisfied all of its obligations with respect to the remaining 6.50% Tangible Equity Units (“TMEDS”) that were issued in May 2012 . Effective May 15, 2015 (the “mandatory settlement date”), the prepaid share purchase contract portion of each outstanding TMED unit was automatically settled at the maximum settlement rate of 5.3879 shares of common stock. Thompson Creek issued a total of 6,105,210 shares of common stock in connection with such settlement. Thompson Creek has also made the final installment payment on the amortizing note portion of each outstanding TMED unit, satisfying in full the principal and interest payments on the TMEDS. The mandatory settlement and final installment payment were made following the terms of the prospectus dated May 8, 2012 , under which the TMEDS were offered in May 2012 .
Thompson Creek Metals Company Inc. engages in mining, milling, processing, and marketing of copper, gold and molybdenum products in the United States and Canada. It operates in three segments: Copper-Gold, US Operations Molybdenum, and Canadian Operations Molybdenum.
Flowers Foods, Inc. (NYSE:FLO), ended its Thursday’s trading session with -6.24% loss, and closed at $21.64.
Flowers Foods, Inc. (FLO) stated financial results for the company’s 16-week first quarter ended April 25, 2015.
First Quarter 2015 Summary Financial Results
Contrast to prior year first quarter
- Sales(1)reduced 0.7% to $1,146 million.
- EBITDA(2)reduced 0.8% to $136 million.
- Net income raised 0.5% to $61 million.
- Diluted earnings per share was unchanged at $0.29.
- Dividends paid raised 17.8% to $0.1325 per share.
(1) Prior period sales have been revised. See explanation in Form 10-Q filed May 28, 2015 and Form 10-K filed February 25, 2015.
(2) Earnings before Interest, Taxes, Depreciation & Amortization; see reconciliation of non-GAAP measures in the financial statements following this release.
First Quarter Highlights
- For the 16-week first quarter of fiscal 2015, sales reduced 0.7% contrast to the prior year first quarter. This decrease reflected a volume decline of 0.9% partially offset by positive price/mix of 0.2%.
- Sales in expansion markets contributed 1.1% to overall sales change during the quarter; driven by the attained bread brands – Wonder, Home Pride, Merita,and Butternut.
- The company generated $118.4 million of cash flow from operations and paid down debt of $56.7 million.
Flowers Foods, Inc. produces and markets bakery products in the United States. It operates through two segments, Direct-Store-Delivery (DSD) and Warehouse Delivery. The DSD segment produces and markets fresh bakery foods, counting fresh breads, buns, rolls, tortillas, and snack cakes.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
